Results 201 to 210 of about 1,095,554 (340)

Factors associated with cardiovascular events after simultaneous liver–kidney transplant from the US Multicenter Simultaneous Liver–Kidney Transplant Consortium

open access: yesHepatology Communications, EarlyView., 2022
Abstract Cardiovascular disease is a leading complication after both liver and kidney transplantation. Factors associated with and rates of cardiovascular events (CVEs) after simultaneous liver–kidney transplant (SLKT) are unknown. This was a retrospective cohort study of adult SLKT recipients between 2002 and 2017 at six centers in six United Network ...
Jennifer Jo   +19 more
wiley   +1 more source

Translational Medicine in Alzheimer's Disease: The Journey of Donanemab From Discovery to Clinical Application

open access: yesChronic Diseases and Translational Medicine, EarlyView.
Donanemab, approved by the U.S. FDA in July 2024, targets amyloid plaques in the brain to treat Alzheimer's disease in patients with mild cognitive impairment or mild dementia. ABSTRACT Substantial research has been conducted to identify an efficient treatment for Alzheimer's disease (AD).
Nandhini Jayaprakash   +1 more
wiley   +1 more source

Study on the efficacy of compound porcine cerebroside and ganglioside injection in patients with ischemic stroke: A randomized, single‐center, open‐label, prospective study

open access: yesIbrain, EarlyView., 2023
Compound porcine perebroside and ganglioside injection (CPCGI) was used to treat ischemic stroke. However, there was no clinical evidence of low‐dose CPCGI. We conducted a clinical study to analyze whether the clinical results of low‐dose and standard‐dose CPCGI in patients with ischemic stroke were different.
Ya Chen   +8 more
wiley   +1 more source

COVID-19 and blood group-related antigens: can natural anti-carbohydrate antibodies provide innate protection from symptomatic SARS-CoV-2 infection? [PDF]

open access: yesFront Med (Lausanne)
Ahmed T   +11 more
europepmc   +1 more source

Amyloid‐Related Imaging Abnormality (ARIA) Beyond the APOE‐ε4 Allele

open access: yesChronic Diseases and Translational Medicine, EarlyView.
Mechanism of action of monoclonal antibodies targeting Aβ in the treatment of AD. (A) Targets of various mAbs. (B) Mechanism of monoclonal antibody‐mediated clearance of Aβ. mAbs facilitate the clearance of Aβ by enhancing microglial‐mediated phagocytosis through the upregulation of TREM2 expression.
Valentinus Besin   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy